Company Overview - Theriva™ Biologics (NYSE American: TOVX) is a diversified clinical-stage company focused on developing therapeutics for cancer and related diseases in areas of high unmet need [2][3] - The company is advancing a new oncolytic adenovirus platform for intravenous, intravitreal, and antitumoral delivery to enhance tumor cell death and improve access to co-administered cancer therapies [2] Lead Candidates - The lead candidates include: - VCN-01: An oncolytic adenovirus that selectively replicates within tumor cells and degrades the tumor stroma barrier, which is a significant barrier to cancer treatment [2] - SYN-004 (ribaxamase): Designed to degrade certain IV beta-lactam antibiotics in the gastrointestinal tract to prevent microbiome damage and reduce the incidence of acute graft-versus-host disease in hematopoietic cell transplant recipients [2] - SYN-020: A recombinant oral formulation of intestinal alkaline phosphatase intended to treat local gastrointestinal and systemic diseases [2] Upcoming Events - Theriva's management team, including CEO Steve Shallcross and General Director Manel Cascallo, will present at the Q1 Investor Summit Virtual on March 11, 2025, at 12:30 PM ET [1][2] - The management team will also participate in one-on-one meetings during the summit [1]
Theriva™ Biologics to Participate in the Q1 Investor Summit Virtual